Merck-Eisai's cancer drug combo meets one main goal in late-stage study

Core Insights - Merck and Eisai's experimental combination treatment for a type of kidney cancer achieved one of its main goals in a late-stage study [1] Company Summary - Merck and Eisai are collaborating on a combination treatment targeting kidney cancer, indicating progress in their clinical development efforts [1]